Current efforts also implies selection of tumor-reactive TILs with the co-stimulatory marker 4-1BB/CD137 (34, 54–59) and alternatively, with PD-1/CD279 (60–62), although these approaches remain to be evaluated under clinical trials (63). This evidence concerns the gene PDCD1 and neoplasm.